Thermo Fisher Scientific is acquiring Olink, a company that provides proteomics analysis tools and services used in drug discovery research. Olink’s growing revenue will help shore up a Thermo Fisher business segment whose sales have fallen due to declining Covid-19 testing demand.

Neko Health recently raised €60 million (about $65.8 million) in Series A financing. The Stockholm-based startup’s medical scanning technology aims to conveniently and affordably collect extensive health data to aid doctors in catching diseases early. The company’s scan takes about 10 minutes and costs €250 (about $275).

Sobi said it plans to seek FDA approval of the gout drug, SEL-212, in 2024. If approved, it would compete against Krystexxa, a Horizon Therapeutics drug projected to become a blockbuster seller.

A randomized, controlled study published in JAMA Open found that patients who engaged in a virtual physical therapy program saw a greater reduction in knee pain than those who continued with their usual care plan at home. However, the study was not blinded, which could affect patients’ self-reported pain scores.

The Nobel Prize in Medicine or Physiology went to Drs. William Kaelin, Gregg Semenza and Peter Ratcliffe. Their research has led to new strategies for treating diseases like cancers and anemia.

On Friday, Novartis presented data at ECTRIMS showing that Arzerra had superior efficacy to Sanofi’s Aubagio. Johnson & Johnson’s Janssen division had presented data for its drug, ponesimod, two days before.

In a phone interview, CEO Jakob Lindberg indicated that data so far showed a study was doing well in terms of progression-free survival.

The Swedish drugmaker acquired rights to the drug from Switzerland-based Novimmune in July for about $50 million, plus about $400 million in payments over eight years.

Sobi buys US rights to Synagis, currently the only drug approved for treating RSV, along with 50 percent of US earnings for its successor, the Phase II MEDI8897.

The challenge with radiation and other cancer therapies is getting the right amount of treatment to the tumor and leaving healthy cells unscathed.

The company will use most of the new funding to build up its sales, business development and marketing operations, with the goal of fully entering the U.S. market by the second quarter of 2017.